((自动化翻译由路透提供，请见免责声明 ))
10月14日 - ** 制药商安进 股价下跌1%，至324.95美元
** Truist Securities 将该公司股票评级从 "买入 "下调至 "持有"，理由是治疗特应性皮炎或湿疹的实验性药物市场竞争 "异常激烈"。
** 券商还将预测价格从 320 美元上调至 333 美元。
** 据分析师称，这种名为rocatinlimab的药物上个月在一项晚期患者研究中取得了成功，但与 (link)，如礼来 的Ebglyss和赛诺菲 -Regeneron 的大片药物Dupixent等已获批准的药物相比还有差距。
** Truist的分析师说，** Rocatinlimab "要想取得成功，必须克服重重困难"，并补充说，该药的安全性问题可能会影响更广泛的机会，因为它曾出现过体温升高和发冷的迹象。
** 券商还预计，即将公布的肥胖症药物 MariTide 的中期数据将 "显示出与之前数据一致的活性"，但表示 "目前的水平已经反映出该项目巨大的价值"。
** 截至上一交易日收盘，股价年累计上涨约 13
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.